Immunovia AB (IMMNOV) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much. This is Jeff Borchening, CEO of Immunovia. I'm very excited that you've chosen to join us today and want to thank those who have taken the time to learn more about Immunovia and our exciting progress over the first quarter. As we continue on our journey of saving lives through early detection of pancreatic cancer, This first quarter marked an important turning point for the company as we transitioned from product development and a focus on the product and clinical development and transitioned to a focus on commercialization and preparing to launch our test later on this year. Before we jump into the presentation, I'd like to share a brief story It's about a woman who reached out to me a few weeks ago. She is a young woman in her 40s. She has a family and also has a family history of pancreatic cancer. She lost her mother to pancreatic cancer at a fairly young age. As you can imagine, this has caused quite a bit of anxiety for her as well as for her family. She's also a person who knows quite a bit about this space. She is a physician researcher at a major institution in the United States. And as she has looked at the current state of the approach for surveillance, she has decided that she's not interested in things like endoscopic ultrasound or an MRI each year because of some of the downsides of using those imaging approaches to monitor for pancreatic cancer. She reached out because she saw the recent clinical data that we had published following the completion of our VERIFY study. She was very excited about the results and wanted to know when the tests will be available. I share her story because it's just one example of how anticipation and excitement is building for the Pancreasure test as we approach launch. On today's call, we'll talk a lit...